MIST Stock Falls 66% Following Complete Response Letter for Cardamyst

Key Takeaways Shares of MIST plunged 66.2% since the CRL issuance, reflecting the delay in the launch of Cardamyst. The company's shares have lost 67.8% so far this year against the industry's 2.2% growth. Despite this regulatory roadblock, analysts remain cautiously optimistic about the drug's prospects. Milestone Pharmaceuticals (MIST) recently announced that the FDA has issued a Complete Response Letter (“CRL”) for its New Drug Application (“NDA”) seeking approval for CARDAMYST (etripamil) nasal spray. ...